
Trevi Therapeutics, Inc. – NASDAQ:TRVI
Trevi Therapeutics stock price today
Trevi Therapeutics stock price monthly change
Trevi Therapeutics stock price quarterly change
Trevi Therapeutics stock price yearly change
Trevi Therapeutics key metrics
Market Cap | 357.46M |
Enterprise value | 21.37M |
P/E | -4.26 |
EV/Sales | N/A |
EV/EBITDA | -0.49 |
Price/Sales | N/A |
Price/Book | 0.31 |
PEG ratio | -0.29 |
EPS | -0.33 |
Revenue | N/A |
EBITDA | -36.80M |
Income | -33.56M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTrevi Therapeutics stock price history
Trevi Therapeutics stock forecast
Trevi Therapeutics financial statements
$6
Potential downside: -18.14%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 0 | -7.14M | |
---|---|---|---|
Sep 2023 | 0 | -7.69M | |
Dec 2023 | 176K | -7.82M | -4443.75% |
Mar 2024 | 0 | -10.90M |
Payout ratio | 0% |
---|
2019 | 5.09% |
---|---|
2020 | |
2021 | |
2022 | |
2023 |
Jun 2023 | 100977000 | 5.90M | 5.85% |
---|---|---|---|
Sep 2023 | 95896000 | 6.28M | 6.56% |
Dec 2023 | 89403000 | 6.85M | 7.67% |
Mar 2024 | 78559000 | 6.22M | 7.92% |
Jun 2023 | -9.87M | 19.63M | -7.66K |
---|---|---|---|
Sep 2023 | -7.27M | 17.98M | 1.51K |
Dec 2023 | -6.35M | 12.84M | -54 |
Mar 2024 | -10.46M | -8.09M | -28K |
Trevi Therapeutics alternative data
Aug 2023 | 22 |
---|---|
Sep 2023 | 30 |
Oct 2023 | 30 |
Nov 2023 | 30 |
Dec 2023 | 25 |
Jan 2024 | 25 |
Feb 2024 | 25 |
Mar 2024 | 25 |
Apr 2024 | 25 |
May 2024 | 25 |
Jun 2024 | 25 |
Jul 2024 | 25 |
Trevi Therapeutics other data
Period | Buy | Sel |
---|---|---|
Oct 2023 | 0 | 785 |
May 2024 | 0 | 87333 |
Aug 2024 | 0 | 52556 |
Sep 2024 | 0 | 61180 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | GALLETTA CHRISTOPHER officer: See Remarks | Stock Option (right to buy) | 15,000 | $0.51 | $7,665 | ||
Option | GALLETTA CHRISTOPHER officer: See Remarks | Common Stock | 15,000 | $0.51 | $7,665 | ||
Option | GOOD JENNIFER L director, officer.. | Common Stock | 1,840 | $1.43 | $2,631 | ||
Sale | GOOD JENNIFER L director, officer.. | Common Stock | 1,840 | $3.04 | $5,586 | ||
Option | GOOD JENNIFER L director, officer.. | Stock Option (right to buy) | 1,840 | $1.43 | $2,631 | ||
Option | GOOD JENNIFER L director, officer.. | Common Stock | 4,219 | $1.43 | $6,033 | ||
Sale | GOOD JENNIFER L director, officer.. | Common Stock | 4,219 | $3.03 | $12,784 | ||
Option | GOOD JENNIFER L director, officer.. | Stock Option (right to buy) | 4,219 | $1.43 | $6,033 | ||
Option | GOOD JENNIFER L director, officer.. | Common Stock | 40,277 | $1.43 | $57,596 | ||
Sale | GOOD JENNIFER L director, officer.. | Common Stock | 40,277 | $3.11 | $125,302 |
Patent |
---|
Application Filling date: 9 May 2022 Issue date: 25 Aug 2022 |
Application Filling date: 24 Mar 2022 Issue date: 14 Jul 2022 |
Application Filling date: 23 Jul 2019 Issue date: 23 Jan 2020 |
Application Filling date: 10 Jul 2019 Issue date: 16 Jan 2020 |
Quarter | Transcript |
---|---|
Q1 2024 11 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 20 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 12 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Trevi Therapeutics stock today?
One share of Trevi Therapeutics stock can currently be purchased for approximately $7.33.
-
When is Trevi Therapeutics's next earnings date?
Unfortunately, Trevi Therapeutics's (TRVI) next earnings date is currently unknown.
-
Does Trevi Therapeutics pay dividends?
No, Trevi Therapeutics does not pay dividends.
-
How much money does Trevi Therapeutics make?
Trevi Therapeutics has a market capitalization of 357.46M.
-
What is Trevi Therapeutics's stock symbol?
Trevi Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TRVI".
-
What is Trevi Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Trevi Therapeutics?
Shares of Trevi Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Trevi Therapeutics's key executives?
Trevi Therapeutics's management team includes the following people:
- Ms. Jennifer L. Good Co-Founder, Chief Executive Officer, Pres & Director(age: 60, pay: $662,640)
- Dr. Thomas R. Sciascia Co-Founder & Chief Medical Officer(age: 72, pay: $476,250)
-
Is Trevi Therapeutics founder-led company?
Yes, Trevi Therapeutics is a company led by its founders Ms. Jennifer L. Good and Dr. Thomas R. Sciascia.
-
How many employees does Trevi Therapeutics have?
As Jul 2024, Trevi Therapeutics employs 25 workers.
-
When Trevi Therapeutics went public?
Trevi Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 7 May 2019.
-
What is Trevi Therapeutics's official website?
The official website for Trevi Therapeutics is trevitherapeutics.com.
-
Where are Trevi Therapeutics's headquarters?
Trevi Therapeutics is headquartered at 195 Church Street, New Haven, CT.
-
How can i contact Trevi Therapeutics?
Trevi Therapeutics's mailing address is 195 Church Street, New Haven, CT and company can be reached via phone at +20 3 3042499.
-
What is Trevi Therapeutics stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Trevi Therapeutics in the last 12 months, the avarage price target is $6. The average price target represents a -18.14% change from the last price of $7.33.
Trevi Therapeutics company profile:

Trevi Therapeutics, Inc.
trevitherapeutics.comNASDAQ
27
Biotechnology
Healthcare
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
New Haven, CT 06510
CIK: 0001563880
ISIN: US89532M1018
CUSIP: 89532M101